Genesis Therapeutics

Staff / Principal Software Engineer - Computational Chemistry / Molecular Dynamics

Remote

Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Pharmaceuticals, Artificial Intelligence, Computational ChemistryIndustries

Requirements

Candidates should possess a Bachelor's degree in Computer Science, Physics, Chemistry, or a related field, and ideally have a Master's or Ph.D. in a relevant discipline. They should have at least 5 years of experience in software development, with a strong focus on computational chemistry, molecular dynamics, or related areas. Experience with Python and scientific computing libraries such as NumPy, SciPy, and MDAnalysis is required. Familiarity with machine learning techniques and experience with data infrastructure scaling are also beneficial.

Responsibilities

The Staff/Principal Software Engineer will build and maintain complex computational chemistry workflows for drug discovery, working closely with computational chemists and CADD scientists to productionize new computational methods for molecular property prediction. They will also be responsible for scaling the company’s data infrastructure to handle large datasets and parallel simulations, and will contribute to the development and maintenance of the GEMS platform. Furthermore, this role involves writing production code, driving projects to completion, and collaborating with a team of accomplished biotech leaders and expert drug hunters to accelerate the discovery of new medicines.

Skills

First principles reasoning
Architectural thinking
API development
Library development
Computational chemistry
Drug discovery
Production code
Data infrastructure scaling
Molecular property prediction
Molecular dynamics
Quantum mechanics (QM)

Genesis Therapeutics

AI-driven drug discovery for pharmaceuticals

About Genesis Therapeutics

Genesis Therapeutics accelerates the development of new medicines by using artificial intelligence in drug discovery. The company combines 3D spatial graph modeling and molecular simulation to identify potential drug candidates and explore new chemical spaces. Unlike its competitors, Genesis Therapeutics focuses on strategic partnerships with other biotech and pharmaceutical companies, generating revenue through upfront payments and future earnings based on drug success. The goal is to transform the drug discovery process and bring new therapies to market.

Key Metrics

Burlingame, CaliforniaHeadquarters
2019Year Founded
$272.5MTotal Funding
SERIES_BCompany Stage
AI & Machine Learning, BiotechnologyIndustries
51-200Employees

Benefits

Competitive salary
Equity
Medical, dental, & vision insurance
401(k) program

Risks

Competition from AI-driven companies like Insilico Medicine and Exscientia is increasing.
Over-reliance on partnerships could lead to financial instability if drugs aren't successful.
Rapid AI advancements may render current models like GEMS obsolete without updates.

Differentiation

Genesis Therapeutics uses AI to accelerate drug discovery with 3D spatial graph modeling.
The GEMS platform integrates deep learning, molecular simulations, and generative AI for drug design.
Strategic partnerships with Eli Lilly and Gilead highlight Genesis' industry collaboration strength.

Upsides

Partnership with NVIDIA enhances GEMS platform for targeting undruggable diseases.
$224 million equity investment boosts research and development capabilities.
Recognition as a 'Fierce 15' company underscores AI's role in breakthrough therapeutics.

Land your dream remote job 3x faster with AI